Longevity biotech NewLimit is edging closer to a major milestone in age‑reversal science: a clinic‑ready epigenetic reprogramming therapy aimed at restoring youthful cell function. The company’s latest progress centers on its liver rejuvenation program, which has produced a lead therapeutic “payload” that could soon advance toward human clinical trials.
Epigenetic reprogramming seeks to reset the gene‑control systems in aging cells that deteriorate over time, causing them to lose specialized functions and become more susceptible to disease. By identifying combinations of transcription factors that can reverse these age‑related changes, NewLimit’s approach targets the biology of aging itself rather than just individual diseases.
According to recent updates, NewLimit has already screened thousands of transcription factor combinations and identified more than 20 that restore youthful characteristics in aged liver cells. One lead candidate is now in advanced preclinical development, engineered via mRNA and showing promising results in lab models, including improved cellular resilience and reduced markers of liver damage.
The company isn’t stopping with the liver: NewLimit has also made strides in rejuvenating immune cells and is exploring applications for other cell types, reflecting its broader mission to develop therapies that improve healthspan by addressing aging at its root.
Source:
Read the original article from Longevity.Technology:
https://longevity.technology/news/newlimit-close-to-clinic-ready-epigenetic-reprogramming-therapy/